丙型肝炎患者中聚乙二醇干扰素的便捷生物学检测方法
Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
作者信息
Boulestin Anne, Kamar Nassim, Legrand-Abravanel Florence, Sandres-Saune Karine, Alric Laurent, Vinel Jean-Pierre, Rostaing Lionel, Izopet Jacques
机构信息
Laboratoire de Virologie EA 2046-IFR 30, CHU PURPAN, Place du Dr Baylac, TSA 40031, 31059 Toulouse Cedex 9, France.
出版信息
Antimicrob Agents Chemother. 2004 Sep;48(9):3610-2. doi: 10.1128/AAC.48.9.3610-3612.2004.
Abstract
The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycol-alpha interferon 2a (PEG-IFN-alpha 2a) and PEG-IFN-alpha 2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-alpha 2a and PEG-IFN-alpha 2b in serum samples from patients undergoing combination therapy.
摘要
水泡性口炎病毒致细胞病变效应降低试验适用于定量聚乙二醇化α-干扰素2a（PEG-IFN-α 2a）和聚乙二醇化α-干扰素2b（PEG-IFN-α 2b）。人血清和利巴韦林不干扰该试验。这种生物测定法已成功用于测定接受联合治疗患者血清样本中的PEG-IFN-α 2a和PEG-IFN-α 2b。
相似文献
1
Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.丙型肝炎患者中聚乙二醇干扰素的便捷生物学检测方法
Antimicrob Agents Chemother. 2004 Sep;48(9):3610-2. doi: 10.1128/AAC.48.9.3610-3612.2004.
2
Pegylation of IFN-alpha and antiviral activity.干扰素-α的聚乙二醇化与抗病毒活性
J Interferon Cytokine Res. 2006 Dec;26(12):849-53. doi: 10.1089/jir.2006.26.849.
3
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.聚乙二醇干扰素α-2b/利巴韦林与干扰素α-2b/利巴韦林联合治疗对慢性丙型肝炎1b型感染且病毒载量高的患者的指数衰减斜率比较。
Intervirology. 2004;47(2):102-7. doi: 10.1159/000077833.
4
Persistence with hepatitis C therapy in the Department of Veterans Affairs.
J Clin Pharm Ther. 2008 Jun;33(3):251-61. doi: 10.1111/j.1365-2710.2008.00912.x.
5
6
A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.一种用于评估聚乙二醇干扰素α-2a对丙型肝炎病毒感染患者的长期影响和成本效益的健康经济模型。
Acta Gastroenterol Belg. 2004 Jan-Mar;67(1):1-8.
7
Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.聚乙二醇干扰素-α-2b对HIV/HCV合并感染患者中HIV和HCV的差异抗病毒作用。
AIDS. 2007 Sep 12;21(14):1855-65. doi: 10.1097/QAD.0b013e32825eaba7.
8
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.聚乙二醇干扰素治疗丙型肝炎期间的抗高尔基体复合物抗体
Liver Int. 2006 Nov;26(9):1148-54. doi: 10.1111/j.1478-3231.2006.01345.x.
9
[Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].[长效国产重组干扰素α-2b的制备及特性]
Ukr Biokhim Zh (1999). 2008 Nov-Dec;80(6):92-100.
10
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.预测丙型肝炎病毒1型感染患者接受聚乙二醇干扰素α-2a/利巴韦林治疗24周后的治疗结果：第0天、第22天、第29天和第6周时丙型肝炎病毒核糖核酸的效用
Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505.
引用本文的文献
1
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.运用药代动力学和病毒动力学模型评估替拉瑞韦、博赛匹韦和聚乙二醇干扰素在经治丙型肝炎病毒感染肝硬化患者三联疗法期间的抗病毒疗效。
Antimicrob Agents Chemother. 2014 Sep;58(9):5332-41. doi: 10.1128/AAC.02611-14. Epub 2014 Jun 30.
2
Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.通过测量MxA启动子激活来定量不同的人α干扰素亚型和聚乙二醇化干扰素活性。
Antimicrob Agents Chemother. 2005 Sep;49(9):3770-5. doi: 10.1128/AAC.49.9.3770-3775.2005.
本文引用的文献
1
Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha.丙型肝炎病毒NS5A基因的遗传异质性及对α干扰素的早期反应
J Infect Dis. 2003 Nov 1;188(9):1367-70. doi: 10.1086/379037. Epub 2003 Oct 13.
2
A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.一种基于复制子的生物测定法，用于检测慢性丙型肝炎患者体内的干扰素。
J Virol Methods. 2003 Jun 30;110(2):201-9. doi: 10.1016/s0166-0934(03)00134-4.
3
Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?预测慢性丙型肝炎的抗病毒治疗反应：准确性如何？速度多快？
J Antimicrob Chemother. 2003 Mar;51(3):487-91. doi: 10.1093/jac/dkg135.
4
Ribavirin quantification in combination treatment of chronic hepatitis C.慢性丙型肝炎联合治疗中利巴韦林的定量分析
Antimicrob Agents Chemother. 2003 Jan;47(1):124-9. doi: 10.1128/AAC.47.1.124-129.2003.
5
Biological assays for interferons.干扰素的生物学检测
J Immunol Methods. 2002 Mar 1;261(1-2):21-36. doi: 10.1016/s0022-1759(01)00570-1.
6
Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega.制定新的和替代的世界卫生组织人α和ω干扰素国际生物标准品。
J Immunol Methods. 2001 Nov 1;257(1-2):17-33. doi: 10.1016/s0022-1759(01)00460-4.
7
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.聚乙二醇化干扰素-α2b：药代动力学、药效学、安全性及初步疗效数据。丙型肝炎干预治疗组。
Clin Pharmacol Ther. 2000 Nov;68(5):556-67. doi: 10.1067/mcp.2000.110973.
8
A pharmacokinetic model for alpha interferon administered subcutaneously.皮下注射α干扰素的药代动力学模型。
Br J Clin Pharmacol. 1999 Apr;47(4):365-71. doi: 10.1046/j.1365-2125.1999.00912.x.
9
Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
J Med Virol. 1998 Feb;54(2):86-91. doi: 10.1002/(sici)1096-9071(199802)54:2<86::aid-jmv3>3.0.co;2-k.
10
Experimental study of transplacental passage of alpha interferon by two assay techniques.两种检测技术对α干扰素经胎盘转运的实验研究
Antimicrob Agents Chemother. 1993 Jun;37(6):1232-7. doi: 10.1128/AAC.37.6.1232.
Zotero 插件